Heska Corp (NASDAQ:HSKA) CEO Kevin S. Wilson sold 3,190 shares of the business’s stock in a transaction dated Friday, November 9th. The shares were sold at an average price of $104.07, for a total value of $331,983.30. Following the sale, the chief executive officer now owns 106,810 shares of the company’s stock, valued at $11,115,716.70. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Shares of NASDAQ:HSKA traded down $2.64 during mid-day trading on Tuesday, reaching $97.76. 27,500 shares of the company traded hands, compared to its average volume of 66,851. The company has a market cap of $781.62 million, a PE ratio of 47.23 and a beta of 0.73. Heska Corp has a 52 week low of $56.59 and a 52 week high of $114.50.

Heska (NASDAQ:HSKA) last announced its quarterly earnings data on Tuesday, November 6th. The medical research company reported $0.46 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.35 by $0.11. The company had revenue of $30.96 million during the quarter, compared to the consensus estimate of $31.14 million. Heska had a return on equity of 11.48% and a net margin of 1.01%. On average, research analysts predict that Heska Corp will post 1.72 EPS for the current year.

A number of equities research analysts have issued reports on the company. BidaskClub downgraded Heska from a “hold” rating to a “sell” rating in a research note on Tuesday, October 9th. TheStreet downgraded Heska from a “b” rating to a “c+” rating in a research note on Monday, August 20th. Zacks Investment Research downgraded Heska from a “hold” rating to a “sell” rating in a research note on Thursday, August 9th. Benchmark assumed coverage on Heska in a research note on Thursday, July 19th. They set a “buy” rating and a $120.00 price target for the company. Finally, ValuEngine downgraded Heska from a “buy” rating to a “hold” rating in a research note on Monday, July 30th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating to the company’s stock. Heska presently has an average rating of “Hold” and an average price target of $107.50.

Several large investors have recently made changes to their positions in the stock. Citadel Advisors LLC grew its stake in shares of Heska by 3.8% during the 3rd quarter. Citadel Advisors LLC now owns 16,190 shares of the medical research company’s stock valued at $1,834,000 after acquiring an additional 592 shares during the period. State Board of Administration of Florida Retirement System grew its stake in shares of Heska by 23.0% during the 2nd quarter. State Board of Administration of Florida Retirement System now owns 3,581 shares of the medical research company’s stock valued at $372,000 after acquiring an additional 670 shares during the period. Globeflex Capital L P grew its stake in shares of Heska by 18.2% during the 2nd quarter. Globeflex Capital L P now owns 5,700 shares of the medical research company’s stock valued at $592,000 after acquiring an additional 877 shares during the period. Legal & General Group Plc grew its stake in shares of Heska by 7.9% during the 2nd quarter. Legal & General Group Plc now owns 13,305 shares of the medical research company’s stock valued at $1,375,000 after acquiring an additional 969 shares during the period. Finally, Rhumbline Advisers grew its stake in shares of Heska by 6.3% during the 2nd quarter. Rhumbline Advisers now owns 16,376 shares of the medical research company’s stock valued at $1,700,000 after acquiring an additional 977 shares during the period. Institutional investors own 87.98% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Heska Corp (HSKA) CEO Kevin S. Wilson Sells 3,190 Shares” was first published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this piece of content on another website, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be read at https://theolympiareport.com/2018/11/13/heska-corp-hska-ceo-kevin-s-wilson-sells-3190-shares.html.

Heska Company Profile

Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal Health segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; HT5 and HEMATRUE veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; COAG veterinary analyzers; Element i immunodiagnostic analyzers; and IV infusion pumps.

Further Reading: Compound Interest and Why It Matters When Investing

Insider Buying and Selling by Quarter for Heska (NASDAQ:HSKA)

Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.